产品
编 号：F011904
分子式：C24H31N5O2
分子量：421.54
分子式：C24H31N5O2
分子量：421.54
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 102394-31-0
产品详情
生物活性：
Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC50 values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively.
体内研究：
Otenzepad (0.5, 1 mg/kg, s.c., in rats) significantly improved win-stay acquisition relative to vehicle-injected controls.Otenzepad (2 mg/kg, s.c., in rats) significantly improved retention relative to vehicle controls.Otenzepad (0.3, 1.0, or 3.0 mg/kg, ip, in mice) potentiates the effects of glucose and reverses the effects of insulin on memory.Animal Model:Forty-eight male Long-Evans rats (325-350 g).
Dosage:0.25, 0.5, 1.0 and 2.0 mg/kg.
Administration:S.C. on the dorsum of the neck once.
Result:Doses of 0.5 and 1.0 mg/kg significantly improved acquisition relative to vehicle controls, while doses of 0.25 and 2.0 mg/kg had no effect.
Animal Model:Adult male Swiss mice (age 60–70 days; weight 25-30 g).
Dosage:0.3, 1.0, or 3.0 mg/kg.
Administration:IP once.
Result:Enhanced retention in an inverted-U dose–response manner, with significant enhancement seen at 1.0 mg/kg (U15,15 = 49, p < 0.02, compared with saline-saline-injected control group).
Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC50 values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively.
体内研究：
Otenzepad (0.5, 1 mg/kg, s.c., in rats) significantly improved win-stay acquisition relative to vehicle-injected controls.Otenzepad (2 mg/kg, s.c., in rats) significantly improved retention relative to vehicle controls.Otenzepad (0.3, 1.0, or 3.0 mg/kg, ip, in mice) potentiates the effects of glucose and reverses the effects of insulin on memory.Animal Model:Forty-eight male Long-Evans rats (325-350 g).
Dosage:0.25, 0.5, 1.0 and 2.0 mg/kg.
Administration:S.C. on the dorsum of the neck once.
Result:Doses of 0.5 and 1.0 mg/kg significantly improved acquisition relative to vehicle controls, while doses of 0.25 and 2.0 mg/kg had no effect.
Animal Model:Adult male Swiss mice (age 60–70 days; weight 25-30 g).
Dosage:0.3, 1.0, or 3.0 mg/kg.
Administration:IP once.
Result:Enhanced retention in an inverted-U dose–response manner, with significant enhancement seen at 1.0 mg/kg (U15,15 = 49, p < 0.02, compared with saline-saline-injected control group).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备